Lapela M, Leskinen-Kallio S, Varpula M, Grénman S, Salmi T, Alanen K, Någren K, Lehikoinen P, Ruotsalainen U, Teräs M
Department of Oncology and Radiotherapy, Turku University, Finland.
J Nucl Med. 1995 Dec;36(12):2196-200.
This study examines the potential of 11C-methionine as a PET tracer in metabolic imaging of benign and malignant ovarian tumors.
Four patients with one or two benign ovarian tumors (endometriomas or cystadenomas), two patients with a tumor of borderline malignancy and seven patients with ovarian cancer were studied with 11C-methionine and PET before laparotomy. CT or MRI were performed as a reference. Tracer uptake was quantitated by calculating tracer standardized uptake values (SUVs) and the kinetic influx constants (Ki values).
Benign or borderline malignant tumors did not accumulate 11C-methionine, whereas all carcinomas had significant uptake. The mean SUV of the primary carcinomas was 7.0 (s.d., 2.2) and the mean Ki was 0.14 min-1 (s.d., 0.1 min-1), but the distribution of tracer uptake was highly heterogenous in four of six tumors.
Ovarian cancer can be imaged with 11C-methionine and PET. This method also may be of value in the differential diagnosis between benign and malignant ovarian neoplasms. Due to physiological accumulations and methodological limitations, the value of 11C-methionine PET in the staging of ovarian cancer appears to be limited.
本研究探讨了¹¹C-蛋氨酸作为正电子发射断层显像（PET）示踪剂在良性和恶性卵巢肿瘤代谢成像中的潜力。
在剖腹手术前，对4例患有1个或2个良性卵巢肿瘤（子宫内膜瘤或囊腺瘤）的患者、2例患有交界性恶性肿瘤的患者和7例患有卵巢癌的患者进行了¹¹C-蛋氨酸和PET检查。以CT或MRI作为对照。通过计算示踪剂标准化摄取值（SUV）和动力学流入常数（Ki值）对示踪剂摄取进行定量分析。
良性或交界性恶性肿瘤不摄取¹¹C-蛋氨酸，而所有癌均有明显摄取。原发性癌的平均SUV为7.0（标准差，2.2），平均Ki为0.14 min⁻¹（标准差，0.1 min⁻¹），但在6个肿瘤中的4个中，示踪剂摄取分布高度不均一。
¹¹C-蛋氨酸和PET可对卵巢癌进行成像。该方法在卵巢良恶性肿瘤的鉴别诊断中也可能具有价值。由于生理性积聚和方法学限制，¹¹C-蛋氨酸PET在卵巢癌分期中的价值似乎有限。
